Zoe Rogers is a Genetics Ph.D. graduate from Stanford University with experience in molecular biology, gene editing techniques like CRISPR/Cas9, and NextGen Sequencing (NGS). She developed a novel method called Tumor Barcode Sequencing (TuBa-Seq) that quantifies the size of tumor lesions in mouse tumor models of lung adenocarcinoma. Zoe also integrated TuBa-Seq with CRISPR/Cas9 to study and eliminate tumor suppressors in different genetic contexts. During her tenure at Karius, Inc. as a Technical Product Manager and Scientist, Zoe gained valuable experience in developing and integrating genetic technologies for patient treatment and diagnosis. She applied her expertise to her role as a Genetic Specialist at Omixy, where she further honed her skills in the implementation of genetic approaches to tackle healthcare challenges. As a former Teaching Assistant at Stanford University, she also demonstrated her ability to teach and mentor. Zoe is now the founder and CEO of her own startup, where she aims to apply her skills to impact the future of patient treatment and diagnostic techniques.